Dendritic cell and melanoma: Dendritic cell therapy combined with hyperthermia in animal studies in mice with melanoma cells, 60% result - complete regression of tumors - compared with 0% in three different control groups, respectively. group with no treatment, hyperthermia only group, only group dendritic cells. Article posted May 2005

June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning

And click here for addresses of clinics in Germany, where dendritic cell therapy is given .

May 21, 2005: Source: Int J Cancer. April 11 2005

Dendritic cell therapy combined with hyperthermia in animal studies in mice with melanoma cells, 60% result - complete regression of tumors - compared with 0% in three different control groups, respectively. group with no treatment, hyperthermia only group, only group dendritic cells. Increased cytotoxic T lymphocyte (CTL) and natural killer (NK) activity was observed in in vitro cytotoxic control in the cured mice treated with the combination therapy, and cured mice after a second injection of B16 melanoma cells had experienced. Although this is an animal study but also seems like the researchers write very important to note that treatment of melanoma with dendritic cell therapy and hyperthermia as well as additional catalyst can work.

Intratumoral injection of immature dendritic cells Enhances antitumor effect of hyperthermia Using magnetic nanoparticles.

Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida T, Honda H.
Department of Biotechnology, School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Japan.

Dendritic cells (DCs) are potent antigen-presenting cells play a pivotal role in That Regulating immune responses in cancer and bone have recently Shown to be activated by heat shock proteins (HSPs). Previously we reported That Hsp70 expression after hyperthermia induces antitumor immunity. Our magnetite cationic liposomes Using hyperthermia system (MCLS) induced necrotic cell death was correlated with Hsp70 That release. In the present study, we Investigated the therapeutic effects of DC therapy combined with MCL-induced hyperthermia on mouse melanoma. In an in vitro study, immature DCs were pulsed with When mouse melanoma B16 cells heated at 43 degrees C, major histocompatibility complex (MHC) class I / II CD80/CD86 costimulatory molecules and CCR7 in the DCs were upregulated, Galanthus tion results in DC maturation. C57BL / 6 mice bearing a melanoma nodule were Subjected to Combination Therapy Using DC immunotherapy and hyperthermia in vivo by Means of tumor-specific hyperthermia Using MCLS and directly injected immature DCs. Mice were Divided enter 4 groups: group I (control), group II (hyperthermia), group III (DC therapy) and group IV (hyperthermia + DC therapy). Complete regression of tumors was observed in 60% of mice in group IV, while no tumor regression was seen among mice in the other groups. Increased cytotoxic T lymphocyte (CTL) and natural killer (NK) activity was observed on in vitro cytotoxicity assay in the cured mice splenocytes Using Treated with combination therapy, and the cured mice rejected a second challenge of B16 melanoma cells. This important study HAS Implications for the application of MCL-induced hyperthermia plus DC therapy in patients with advanced malignancies as a novel cancer therapy. (C) 2005 Wiley-Liss, Inc..

PMID: 15825167 [PubMed - as supplied by publisher]